Fibrin-specific Probe Labeling
Fibrin-specific Probe Labeling - Related Videos
12:16
Robust 3D DNA FISH Using Directly Labeled Probes
0 Views •
Cited by 49 •
2013
We describe a robust and versatile protocol for analyzing nuclear architecture by 3D DNA FISH using directly labeled fluorescent probes.
03:31
Labeling DNA Probes
0 Views •
2021
DNA probes are fragments of DNA labeled with a reporter tag to enable their detection or purification. The resulting labeled DNA probes can then hybridize to target nucleic acid sequences through complementary base-pairing, and may be used to recover or identify these regions. Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...
01:16
Clot Retraction and Fibrinolysis
0 Views •
2024
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
05:57
Peroxisome Staining in Mammalian Cells Using Peroxisome-Specific Probes
0 Views •
2025
PeroxiSPY probes are used to detect peroxisomes in mammalian cells. Here we demonstrate how to use the probes to stain peroxisomes in live and fixed cells.
11:15
In Situ Detection of Bacteria within Paraffin-embedded Tissues Using a Digoxin-labeled DNA Probe Targeting 16S rRNA
0 Views •
Cited by 16 •
2015
Here a method to localize bacteria within paraffin-embedded tissues using DIG-labeled 16S rRNA-targeting DNA probes has been described. This protocol can be applied to study the role of bacteria in various diseases such as periodontitis, cancers, and inflammatory immune diseases.
FAQs
The key distinction comes from selective molecular recognition. Binding ligands, including antibodies or fibrin-recognizing peptides, are designed to recognize fibrin within clots or deposits rather than circulating fibrinogen. This selectivity allows a detected signal to indicate coagulation-related material at a particular site, helping researchers separate formed clot material from its soluble precursor in biological samples or living systems.
The binding ligand provides molecular targeting, while the attached detectable tag makes the interaction observable. Antibodies and fibrin-recognizing peptides contribute recognition of the fibrin target, and the tag enables its location to be detected. Together, these components connect biochemical specificity with an imaging readout, allowing fibrin distribution to be examined rather than inferred only from general vascular injury.
Spatial information can connect vascular changes with nearby tissue responses. In the nervous system, fibrin accumulation may be examined alongside blood-brain barrier disruption and neuroinflammation, while labeling can also reveal vascular thrombosis or hemorrhage. Mapping where the signal occurs therefore supports investigation of how vascular injury relates to local pathological processes in neurological disease.
A typical workflow uses a fibrin-binding probe carrying a detectable tag, introduces or applies it to a biological sample or living system, and then detects where the probe has accumulated. The resulting pattern is interpreted as evidence of fibrin-containing clots or deposits, with attention to whether the signal appears in regions relevant to vascular injury or tissue responses.
Researchers can apply it when they need to examine vascular thrombosis, hemorrhage, or fibrin accumulation associated with blood-brain barrier disruption and neuroinflammation. Its relevance extends to studies of stroke and other neurological disorders because the signal can help connect coagulation-related material with changes occurring in nervous-system tissue, providing a molecular imaging perspective on vascular pathology.
The approach can help evaluate whether an intervention is associated with changes in fibrin-containing clots or deposits. By detecting the target within biological samples or living systems, investigators can examine fibrin distribution in disease-related settings and relate those observations to vascular injury and local tissue responses. This supports assessment of strategies directed specifically at fibrin rather than fibrinogen.